A meta-analysis on efficacy of anti-platelet agents and anticoagulants for preventing stroke in patients with nonvalvular atrial fibrillation

To evaluate the efficacy and security of anti-platelet and anticoagulant therapy on prevention of ischemic stroke in patients with nonvalvular atrial fibrillation (NAF). We searched PubMed, EMbase, CENTREN and its affiliated clinical trial registration data center, CBMdisc, VIP, and CNKI databases f...

Full description

Saved in:
Bibliographic Details
Published inZhōnghuá xīnxuèguănbìng zázhì Vol. 39; no. 3; p. 262
Main Authors Tu, Rong-Hui, Zhong, Guo-Qiang, Zeng, Zhi-Yu, Wu, Wei-Feng, He, Yan
Format Journal Article
LanguageChinese
Published China 01.03.2011
Subjects
Anticoagulants - therapeutic use
Atrial Fibrillation - complications
Atrial Fibrillation - therapy
Humans
Platelet Aggregation Inhibitors - therapeutic use
Stroke - etiology
Stroke - therapy
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:To evaluate the efficacy and security of anti-platelet and anticoagulant therapy on prevention of ischemic stroke in patients with nonvalvular atrial fibrillation (NAF). We searched PubMed, EMbase, CENTREN and its affiliated clinical trial registration data center, CBMdisc, VIP, and CNKI databases from establishment to Dec 2009 to identify randomized controlled trials (RCTs) covering the use of anti-platelet agents and anticoagulants for patients with NAF. Meta-analysis was performed by using RevMan 5.0 software after the strict evaluation of the methodological quality of the included RCTs. Fourteen RCTs involving 15 880 patients were include. Compared with placebo or no use of anti-platelet drugs, antiplatelet therapy didn't reduce ischemic stroke (RR = 0.83, 95%CI 0.68 to 1.00, P = 0.05), systemic emboli (RR = 0.71, 95%CI 0.34 to 1.51, P = 0.38) and all-cause mortality (RR = 0.88, 95%CI 0.73 to 1.07, P = 0.21) while significantly increased the major bleeding (RR = 2.88, 95%CI 1.21 to 6.86, P = 0.02) in pati
ISSN:0253-3758